新型口服抗凝剂可用于冠状动脉瘤吗？
Could the Novel Oral Anticoagulants Be Used for Coronary Artery Aneurysm?
作者信息
Yan Quanxiang, Ning Libing, Jian Yu, Yang Wencong, Yuan Qinghua, Du Zhimin
机构信息
Cardiovasology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.
Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
出版信息
Case Rep Med. 2020 Apr 25;2020:5073814. doi: 10.1155/2020/5073814. eCollection 2020.
Coronary artery aneurysms (CAAs) are uncommon in coronary angiography, and left main coronary artery aneurysms are rare. There is no consensus for the treatment of CAAs. A young patient with left coronary artery aneurysm diagnosed by coronary angiography and with recurrent acute myocardial infarction was treated with rivaroxaban and aspirin. The patient had no angina for 6 months. Novel oral anticoagulants combined with antiplatelet agents may be appropriate for the treatment of CAAs.
冠状动脉瘤（CAAs）在冠状动脉造影中并不常见，而左主干冠状动脉瘤则更为罕见。目前对于CAAs的治疗尚无共识。一名通过冠状动脉造影诊断为左冠状动脉瘤且反复发生急性心肌梗死的年轻患者接受了利伐沙班和阿司匹林治疗。该患者6个月来未出现心绞痛。新型口服抗凝剂联合抗血小板药物可能适用于CAAs的治疗。
Zotero 插件